EUCTR2019-001991-12-GB进行中（未招募）1 期
A Phase II, randomised, observer-blind, placebo controlled multi-country study to assess the safety, reactogenicity and immunogenicity of a single intramuscular dose of GSK Biologicals’ investigational RSV Maternal unadjuvanted vaccine (GSK3888550A), in healthy pregnant women aged 18 to 40 years and infants born to vaccinated mothers - RSV MAT-004
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 300
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •Maternal subjects
- •?Subjects who, in the opinion of the investigator, can and will comply with the requirements of the protocol.
- •?Subjects who give written or witnessed/thumb printed informed consent after the study has been explained according to local regulatory requirements, and before performing any study specific procedures are performed.
- •The informed consent given at screening should (consistent with local regulations / guidelines) either:
- •- include consent for both the maternal subject's participation and participation of the infant after the infant’s birth, or
- •- include consent for the maternal subject's participation and expressed willingness to consider permitting the infant to take part after the infant's birth.
- •Both mother and father should consent if local regulations/guidelines require it.
- •?Age 18 to 40 years, inclusive, when informed consent is given.
- •?Pre-pregnancy BMI 18.5 to 34.9, inclusive
- •?Healthy as established by medical history and clinical examination before entering into the study.
- •?At 28^0/7 to 33^6/7 weeks of gestation at the time of study vaccination (Visit 1), as established by last menstrual period (LMP) date corroborated by first or second trimester ultrasound examination (U/S).
- •* If LMP and U/S do not correlate, default to U/S gestational age assessment. The level of diagnostic certainty of the gestational age should be established by using the Global Alignment of Immunisation safety Assessment in pregnancy gestation age assessment tool
- •?Subject satisfying screening requirements
- •?Singleton pregnancy
- •?HIV negative, as assessed by local standard of care serologic tests conducted during the current pregnancy and before enrolment (Visit 1).
- •?No fetal genetic abnormalities.
- •?No significant congenital malformations, as assessed by level 2 ultrasound (also known as a fetal anomaly untrasound scan or fetal morphology assessment) conducted after 18 weeks of gestation
- •?Willing to provide cord blood
- •?Willing to have the infant followed-up after delivery for a period of 12 months
- •?Does not plan after delivery to give the infant for adoption or place the infant in care
- •Note that women whose pregnancies resulted from Assisted Reproductive Technologies may be enrolled if they meet all inclusion criteria and none of the exclusion criteria.
- •Infant subjects
- •?Live-born from the study pregnancy.
- •?Re-signed (confirmed) written or witnessed/thumb printed informed consent for study participation of the infant obtained from the infant’s mother and/or father and/or legally authorized representative, as applicable by local law, before performing any study specific procedure.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 300
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Maternal subjects
- •Medical conditions
- •?History of allergic disease or reactions likely to be exacerbated by any component of the RSV vaccine
- •?Hypersensitivity to latex
- •?Significant complications in the current pregnancy such as:
- •?Gestational hypertension at =20 weeks of gestation in the absence of proteinuria in a woman with a previously normal blood pressure
- •?Gestational diabetes which is not controlled by diet and exercise
- •?Pre-eclampsia
- •?Eclampsia during current pregnancy
- •?Intrauterine growth restriction
- •?Placenta previa
- •?Placental abruption, placenta accreta/percreta/increta, chorioamnionitis or any abnormalities that in the opinion of Investigator can impair the maternal-fetal circulation
- •?Polyhydramnios
- •?Oligohydramnios
- •?Cervical suture in place
- •?Preterm labour or history of preterm labour in the current pregnancy
- •?Ongoing medical intervention to prevent preterm delivery or medical treatment for suspected preterm delivery
- •?Cholestasis
- •?Other pregnancy-related complications that in the Investigator’s judgement would preclude participation of the subjects in an investigational vaccine trial or might pose risk to the subject due to participation in the study
- •?Significant structural abnormalities of the uterus or cervix
- •?History of prior stillbirth or neonatal death
- •?History of preterm birth
- •?History of =2 spontaneous abortions
- •?Known or suspected HBV or HCV infection, based on medical history and clinical presentation
- •?Known or suspected infection during the current pregnancy with Toxoplasma, Parvovirus B19, Syphilis, Zika, Rubella, Varicella, CMV or primary genital Herpes Simplex, based on medical history and clinical presentation
- •?Active infection with tuberculosis, based on medical history and clinical presentation
- •?Known or suspected impairment of the immune system or autoimmune disorder (based on medical history and physical examination; no laboratory testing required)
- •?Lymphoproliferative disorder or malignancy within 5 years before vaccination (excluding effectively treated non-melanoma skin cancer)
- •?Any clinically significant grade 1 hematological and/or biochemical laboratory abnormalities identified at screening, which are clinically significant for pregnant women in the second and third trimester
- •?Grade = 2 hematological and/or biochemical laboratory abnormalities identified at screening being clinically significant for pregnant women in the second and third trimester
- •?Acute or chronic clinically significant conditions, that might pose additional risk to the subject due to participation in the study
- •?Any conditions that, may interfere with subject’s ability to comply with study procedures or receipt of prenatal care
- •?Any condition which, would increase the risks of study participation to the unborn infant
- •Prior/Concomitant therapy
- •?Prior receipt of a COVID-19 vaccine
- •?Prior receipt of an RSV vaccine
- •?Use of any investigational or non-registered product other than the study vaccine(s)/product(s) during the period beginning 29 days before the dose of study vaccine/product or planned use during the study period
- •?Planned administration / administration of any vaccine within 29 days before study vaccine administration and through Day 43 post-delivery, except seasonal influenza vaccines and dTpa/Tdap or tetanus, which may be administered according to standard of care = 15 days before or after study vaccination
- •?Administration of immunoglobulins, blood products or plasm
研究者
相似试验
进行中（未招募）
1 期
Study of safety, reactogenicity and immunogenicity of GlaxoSmithKline’s (GSK)Respiratory Syncytial Virus (RSV)maternal unadjuvanted vaccine in healthy pregnant women (aged 18 to 40 years) and their infants.Healthy Volunteers (prevention of lower respiratory tract illness)EUCTR2019-001991-12-FIGlaxoSmithKline Biologicals300
进行中（未招募）
1 期
Study of safety, reactogenicity and immunogenicity of GlaxoSmithKline’s (GSK)Respiratory Syncytial Virus (RSV)maternal unadjuvanted vaccine in healthy pregnant women (aged 18 to 40 years) and their infants.Healthy Volunteers (prevention of lower respiratory tract illness)EUCTR2019-001991-12-ESGlaxoSmithKline S.A.534
进行中（未招募）
1 期
Study of safety, reactogenicity and immunogenicity of GlaxoSmithKline’s (GSK)Respiratory Syncytial Virus (RSV)maternal unadjuvanted vaccine in healthy pregnant women (aged 18 to 40 years) and their infants.Healthy Volunteers (prevention of lower respiratory tract illness)EUCTR2019-001991-12-FRGlaxoSmithKline Biologicals150
进行中（未招募）
1 期
A phase II, observer-blind, randomised, placebo-controlled, adjuvant-dose selection, multicenter prophylactic vaccination study to evaluate the immunogenicity and safety of GSK Biologicals’ herpes zoster vaccine, gE/AS01B, in comparison to gE combined with ½ dose AS01B adjuvant (gE/AS01E), to unadjuvanted gE (gE/Saline), and to Saline (placebo) when administered twice in subjects aged 50 years and older. - Zoster-010Primary immunisation of subjects aged 50 years or older against herpes zoster (HZ).The study population includes healthy volunteer males and females in the age ranges: 50-59 years of age (YOA), 60-69 YOA, and more than 70 YOA.EUCTR2008-005120-86-CZGlaxoSmithKline Biologicals396
进行中（未招募）
1 期
A study to evaluate the safety, reactogenicity and immunogenicity of GSK Biologicals’ investigational vaccine GSK2838504A when administered to patients with persistent airflow obstructioEUCTR2013-003062-13-GBGlaxoSmithKline Biologicals145